Valuation: Insmed Incorporated

Market Cap 29.43B 25.47B 23.81B 21.76B 41.01B 2,807B 41.65B 279B 110B 1,404B 110B 108B 4,676B P/E 2026 *
-88.1x
P/E 2027 * 120x
Enterprise Value 28.8B 24.93B 23.3B 21.3B 40.13B 2,746B 40.76B 273B 107B 1,374B 108B 106B 4,576B EV / Sales 2026 *
16x
EV / Sales 2027 * 9.77x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
1 week+36.87%
Current month+36.66%
1 month+16.56%
3 months+32.96%
6 months-9.29%
Current year-22.58%
1 week 98.64
Extreme 98.64
137.7
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%+36.87%+23.00%+493.09% 29.43B
+4.21%+25.56%+77.96%+104.49% 70.85B
0.00%+5.14%+38.36%+68.33% 55.41B
-0.30%+13.64%+54.71%+6.07% 24.12B
-0.93%+0.60%-16.89%-12.00% 23.31B
+0.50%+6.66%+47.55%-21.42% 18.37B
+7.26%+14.16%+221.03%+393.89% 16.99B
0.00%+9.69%+31.01%+584.59% 16.1B
-2.05%-3.81%+40.40%+150.40% 13.12B
+0.78%+2.70%+437.94%+204.90% 12.48B
Average +1.21%+360.97%+95.51%+197.23% 28.02B
Weighted average by Cap. +1.63%+338.92%+72.72%+163.49%

Financials

2026 *2027 *
Net sales 1.8B 1.56B 1.46B 1.33B 2.52B 172B 2.55B 17.12B 6.72B 86.11B 6.78B 6.63B 287B 2.89B 2.51B 2.34B 2.14B 4.03B 276B 4.1B 27.47B 10.78B 138B 10.87B 10.63B 460B
Net income -326M -282M -264M -241M -454M -31.1B -462M -3.09B -1.21B -15.56B -1.22B -1.2B -51.82B 233M 202M 189M 172M 325M 22.22B 330M 2.21B 867M 11.12B 875M 856M 37.02B
Net Debt -632M -547M -511M -467M -880M -60.26B -894M -6B -2.35B -30.15B -2.37B -2.32B -100B -1.16B -1B -936M -855M -1.61B -110B -1.64B -10.97B -4.31B -55.19B -4.34B -4.25B -184B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-10 US$134.75 +2.78% 3,630,056
26-08-07 US$131.10 -1.09% 4,904,624
26-08-06 US$132.55 +33.86% 12,036,146
26-08-05 US$99.02 +0.27% 4,899,602
26-08-04 US$98.75 +0.30% 4,290,804
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
134.75USD
Average target price
200.05USD
Spread / Average Target
+48.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock